Based on these results, we would suggest that the interesting common property between MSP and MSL are its effect on mitochondrial and nucleous functionality, which might indicate a potential metabolic impact of RTK inhibitor treatment on liver and pancreatic cancer. The gene discussed is MFN2; the disease is familial pancreatic carcinoma.